News

CEO, Anders Hultman, Commenting on FDA delay due to Covid-19

Jan 20, 2021

This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA delay in an interview with Redeye.

Strategy update: IDL Diagnostics

Nov 28, 2025 | , ,

A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their...

read more

Thesis projects at IDL Diagnostics.

Jun 10, 2025 | ,

We are pleased to recognize four outstanding students who have recently completed their thesis projects with us at IDL Diagnostics. The projects started in January 2025. Putri Rezqita and Yu Shi from Karolinska Institutet contributed their deep knowledge in health and...

read more